These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 18610807)

  • 1. Advances in therapeutic immunomodulation of IgE-mediated respiratory disease.
    Settipane RA
    Med Health R I; 2008 Jun; 91(6):187-90, 193-5. PubMed ID: 18610807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in upper airway diseases and allergen immunotherapy in 2007.
    Saltoun C; Avila PC
    J Allergy Clin Immunol; 2008 Sep; 122(3):481-7. PubMed ID: 18694591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases.
    Chang TW; Wu PC; Hsu CL; Hung AF
    Adv Immunol; 2007; 93():63-119. PubMed ID: 17383539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases.
    D'Amato G
    Eur J Pharmacol; 2006 Mar; 533(1-3):302-7. PubMed ID: 16464445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis.
    Busse WW; Massanari M; Kianifard F; Geba GP
    Curr Med Res Opin; 2007 Oct; 23(10):2379-86. PubMed ID: 17711616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoglobulin E-mediated airway inflammation is active in most patients with asthma.
    Hayden ML
    J Am Acad Nurse Pract; 2007 Sep; 19(9):439-49. PubMed ID: 17760568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab.
    Nowak D
    Respir Med; 2006 Nov; 100(11):1907-17. PubMed ID: 16949266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulin E blockade in the treatment of asthma.
    Kuhn R
    Pharmacotherapy; 2007 Oct; 27(10):1412-24. PubMed ID: 17896896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omalizumab: efficacy in allergic disease.
    Spector S
    Panminerva Med; 2004 Jun; 46(2):141-8. PubMed ID: 15507883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-immunoglobulin E therapy with omalizumab for asthma.
    Hendeles L; Sorkness CA
    Ann Pharmacother; 2007 Sep; 41(9):1397-410. PubMed ID: 17698897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation.
    Holgate S; Casale T; Wenzel S; Bousquet J; Deniz Y; Reisner C
    J Allergy Clin Immunol; 2005 Mar; 115(3):459-65. PubMed ID: 15753888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New perspectives in the treatment of allergic rhinitis and asthma in children.
    Baena-Cagnani CE; Passalacqua G; Gómez M; Zernotti ME; Canonica GW
    Curr Opin Allergy Clin Immunol; 2007 Apr; 7(2):201-6. PubMed ID: 17351477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with a combination of anti-IgE and specific immunotherapy for allergic rhinitis and asthma.
    Hamelmann E; Rolinck-Werninghaus C; Wahn U; Kopp MV
    Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():303-13; discussion 313-5. PubMed ID: 20799475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of US Food and Drug Administration-cleared IgE antibody assays in the presence of anti-IgE (omalizumab).
    Hamilton RG
    J Allergy Clin Immunol; 2006 Apr; 117(4):759-66. PubMed ID: 16630931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of the total IgE level by omalizumab in children and adolescents.
    Steiss JO; Strohner P; Zimmer KP; Lindemann H
    J Asthma; 2008 Apr; 45(3):233-6. PubMed ID: 18415832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
    Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
    Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoglobulin E: role in asthma and allergic disease: lessons from the clinic.
    Owen CE
    Pharmacol Ther; 2007 Jan; 113(1):121-33. PubMed ID: 17000005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newer therapies for asthma: a focus on anti-IgE.
    Babu KS; Holgate ST
    Indian J Chest Dis Allied Sci; 2002; 44(2):107-15. PubMed ID: 12026249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacological basis of anti-IgE therapy.
    Chang TW
    Nat Biotechnol; 2000 Feb; 18(2):157-62. PubMed ID: 10657120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.